Cytokinetics: CEO Talks Down Buyout Prospects [Seeking Alpha]
Cytokinetics, Incorporated (CYTK)
Last cytokinetics, incorporated earnings: 3/3 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.cytokinetics.com/investor-overview
Company Research
Source: Seeking Alpha
Blum said the company had not initiated a sale process and emphasized the focus on business development and partnerships, particularly in Japan. In the absence of a buyout, the attention will now turn to data presentations of aficamten, regulatory submissions expected in Q3 and Q4. Cytokinetics is now trading at attractive levels as a standalone entity. Looking for more investing ideas like this one? Get them exclusively at Growth Stock Forum. Learn More » Shares of Cytokinetics NASDAQ: CYTK ) are down 40% from early January highs as bullish investor sentiment driven by positive SEQUOIA phase 3 results of aficamten and buyout speculation waned, initially after new rumors surfaced that Novartis walked away, and more recently, after CEO Blum talked down the buyout prospects on the earnings call in late February, and this week at the Leerink Healthcare Conference. The stock is down more than 20% since my late December 2023 article where I highlighted the very strong SEQUOIA ph
Show less
Read more
Impact Snapshot
Event Time:
CYTK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CYTK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CYTK alerts
High impacting Cytokinetics, Incorporated news events
Weekly update
A roundup of the hottest topics
CYTK
News
- Cytokinetics to Announce First Quarter Results on May 8, 2024GlobeNewswire
- Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress [Yahoo! Finance]Yahoo! Finance
- Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 CongressGlobeNewswire
- Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $108.00 price target on the stock.MarketBeat
- Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $86.00 price target on the stock.MarketBeat
CYTK
Earnings
- 2/27/24 - Miss
CYTK
Sec Filings
- 4/26/24 - Form 8-K
- 4/25/24 - Form 4
- 4/25/24 - Form 144
- CYTK's page on the SEC website